Illumina, Inc.
http://www.illumina.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Illumina, Inc.
Federal Small Business Research Grant Programs At Risk Of Expiration, AdvaMed Says
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs will shut down on 30 September if Congress doesn’t act to renew them – but some US senators say the programs are wasteful and may funnel research overseas.
Jury Awards Nearly $334M To MGI Tech In Illumina Patent Suit
The jury said the infringement, which involved patents on two-channel sequencing chemistry technology, had been “willful” and turned down Illumina’s counterclaims.
Deerfield And Illumina Join Forces To Fund New Discoveries, New Companies
Investor Deerfield Management and genomic sequencing giant Illumina entered into a five-year partnership to identify novel targets and drug candidates that may be spun out into new companies.
Illumina Wins Injunction Keeping BGI Sequencers Off US Market
BGI, and its subsidiary MGI, can’t sell the infringing products in the US until after Illumina’s patents expire.
Company Information
- Industry
- Pharmaceuticals
- Services
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Nanotechnology, Chips, etc.
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- GenoLogics Life Sciences Software
- GRAIL Inc.
- Myraqa
- Verinata Health
- Illumina Ventures